HealthDay - THURSDAY, Oct. 9 (HealthDay News) -- People with kidney cancer, regardless of age, seem to benefit from and tolerate sorafenib drug therapy equally well, a new study says.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.